Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429587 | 0.84 | HTR6 (0.59) | HTR6KDM4EHTR2AHTR2CDRD3 | |
| SCHEMBL4420871 | 0.84 | HTR6 (0.61) | HTR6KDM4EHTR2AHTR2CDRD3 | |
| SCHEMBL4428396 | 0.82 | HTR6 (0.61) | HTR6KDM4EHTR2AHTR2CDRD3 | |
| SCHEMBL4417941 | 0.82 | HTR6 (0.60) | HTR6KDM4EHTR2AHTR2CDRD3 | |
| SCHEMBL4419390 | 0.81 | HTR6 (0.57) | HTR6KDM4EHTR2AHTR2CDRD3 | |
| SCHEMBL4420503 | 0.80 | HTR6 (0.61) | HTR6KDM4EHTR2AHTR2CDRD3 | |
| SCHEMBL4419770 | 0.80 | HTR6 (0.60) | HTR6KDM4E | |
| SCHEMBL4425213 | 0.78 | HTR6 (0.54) | HTR6KDM4EHTR2AHTR2CDRD3 | |
| SCHEMBL4419809 | 0.77 | HTR6 (0.55) | HTR6KDM4EHTR2AHTR2CDRD3 | |
| SCHEMBL4420697 | 0.75 | HTR6 (0.32) | HTR6CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544701-B2 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-09 | — | — | US | claimed |
| EP-1654258-A1 | SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005009996-A1 | SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-02-03 | — | — | WO | claimed |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | claimed |
| US-7544701-B2 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-09 | — | — | US | disclosed |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1B | HTR6 1/4885KDM4E 2965/4885HTR2A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.